New drug shows promise for Hard-to-Treat nasal polyps

NCT ID NCT06914908

ENROLLING_BY_INVITATION Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 02, 2026 · Updated 2 times

Summary

This study looks at the long-term safety and effectiveness of lunsekimig, an injectable drug, in adults with chronic sinusitis and nasal polyps that are not well controlled. Participants have already completed a previous lunsekimig study and will continue treatment for up to 52 weeks. The goal is to see if the drug remains safe and helps control symptoms over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: lunsekimig (injection) and mometasone furoate nasal spray
What this could lead to: If successful, this could provide a long-term treatment option for people with nasal polyps that are not well controlled by current therapies.
What could go wrong: This is a small, early-phase extension study with no placebo group, so results may not confirm effectiveness. Side effects are still being evaluated.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC RHINOSINUSITIS WITH NASAL POLYPS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC RHINOSINUSITIS WITH NASAL POLYPS

Contacts and locations

Locations

Alamo ENT Associates- Site Number : 8400001

San Antonio, Texas, 78258, United States
ENT Associates of Texas - McKinne- Site Number : 8400014

McKinney, Texas, 75070, United States
Eastern Virginia Medical School (EVMS) Medical Group- Site Number : 8400008

Norfolk, Virginia, 23510, United States
Essential Medical Research- Site Number : 8400020

Tulsa, Oklahoma, 74137, United States
Investigational Site Number : 0320001

Buenos Aires, 1121, Argentina
Investigational Site Number : 0320002

Rosario, Santa Fe Province, 2000, Argentina
Investigational Site Number : 0320003

Mendoza, 5500, Argentina
Investigational Site Number : 0560001

Leuven, 3000, Belgium
Investigational Site Number : 0560002

Ghent, 9000, Belgium
Investigational Site Number : 1000001

Sofia, 1612, Bulgaria
Investigational Site Number : 6160001

Warsaw, Masovian Voivodeship, 00-909, Poland
Investigational Site Number : 6160002

Krakow, Lesser Poland Voivodeship, 30-033, Poland
Investigational Site Number : 6160003

Katowice, Silesian Voivodeship, 40-611, Poland
Investigational Site Number : 6160004

Poznan, Greater Poland Voivodeship, 60-693, Poland
Investigational Site Number : 6160005

Warsaw, Masovian Voivodeship, 02-507, Poland
Investigational Site Number : 6160007

Wroclaw, Lower Silesian Voivodeship, 50-750, Poland
Investigational Site Number : 8260001

Newcastle upon Tyne, NE7 7DN, United Kingdom
Investigational Site Number : 8260003

Manchester, M13 9wl, United Kingdom
Investigational Site Number : 8260004

Gloucester, Gloucestershire, GL1 3NN, United Kingdom
McGovern Medical School - UT Physicians Dermatology - Bellaire Station- Site Number : 8400017

Bellaire, Texas, 77401, United States
Modena Allergy + Asthma- Site Number : 8400005

La Jolla, California, 92037, United States
Pharmaceutical Research & Consulting- Site Number : 8400004

Dallas, Texas, 75231, United States
Sacramento Ear Nose & Throat - Roseville- Site Number : 8400003

Roseville, California, 95661, United States
Treasure Valley Medical Research- Site Number : 8400002

Boise, Idaho, 83706, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.